Experimental drug tested for Hard-to-Treat cancers
NCT ID NCT04504942
Summary
This study tested an experimental drug called leronlimab in patients with advanced solid tumors that had a specific marker (CCR5+). The main goals were to check the drug's safety and see if it could help control the cancer. Patients received weekly injections of leronlimab, often alongside their standard cancer treatments, until their disease progressed or side effects became too severe.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Quest Clinical Research
San Francisco, California, 94115, United States
Conditions
Explore the condition pages connected to this study.